“Amedica announced FDA clearance of the Valeo C+CsC with Lumen Interbody Fusion Device. This is a composite spinal fusion implant that combines different densities of medical grade silicon nitride ceramic. An outer shell of solid silicon nitride is manufactured around a porous core, called CsC (Cancellous structured Ceramic). The Valeo C+CsC device is already used in Europe, and the Valeo C+CsC with Lumen is the introduction of this porous technology in the USA.”,” Maxim Group’s analyst wrote.
Several other analysts also recently commented on the stock. ValuEngine raised shares of Amedica from a strong sell rating to a sell rating in a research report on Friday, February 2nd. Ladenburg Thalmann Financial Services downgraded shares of Amedica from a buy rating to a neutral rating in a report on Monday, November 27th.
An institutional investor recently raised its position in Amedica stock. Vanguard Group Inc. increased its position in shares of Amedica Co. (NASDAQ:AMDA) by 7.1% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 595,866 shares of the medical equipment provider’s stock after purchasing an additional 39,603 shares during the quarter. Vanguard Group Inc. owned approximately 2.26% of Amedica worth $226,000 at the end of the most recent quarter. Institutional investors and hedge funds own 5.62% of the company’s stock.
Amedica Corporation is a commercial biomaterial company. The Company is a vertically integrated silicon nitride orthopedic medical device manufacturer. It is focused on using its silicon nitride ceramic technology platform to develop, manufacture and sell a range of medical devices. It is also engaged in developing wear- and corrosion-resistant implant components for hip and knee arthroplasty.
Receive News & Ratings for Amedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedica and related companies with MarketBeat.com's FREE daily email newsletter.